RxDoctor Payments Data

Robert Eisenberg, MD

Urology · Modesto, CANPI 1821014820

Payments from drug & device makers

$6,109in general payments, 2019–2025

Across 12 payments — averaging $509.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Varian Medical Systems, Inc.$6K
  • Boston Scientific$159
  • Astellas Pharma US Inc$100
  • Rochester Medical Corporation$42
  • Urogen Pharma, Inc.$34
  • Merck$31
  • plus $24 from 1 others

What the payments were for

  • Speaking & faculty fees$5,00082%
  • Travel & lodging$72012%
  • Food & beverage$2554%
  • Education$1342%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Varian Medical Systems, Inc.3$5,720
Boston Scientific2$159
Astellas Pharma US Inc1$100
Rochester Medical Corporation2$42
Urogen Pharma, Inc.2$34
Merck1$31
AbbVie1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,109 in reported general payments places this provider in the 65th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$88,412
Medicare patients
267
Services billed
1,305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron60$38,924
ElmironPentosan Polysulfate Sodium18$19,873
Tamsulosin Hcl382$8,161
Finasteride148$2,332
Bethanechol Chloride21$2,310
Desmopressin Acetate15$2,297
Potassium Citrate ErPotassium Citrate14$2,277
Dutasteride39$1,823
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst31$1,505
Bicalutamide35$1,084
Testosterone Cypionate19$617
Terazosin Hcl37$543
Oxybutynin Chloride ErOxybutynin Chloride22$452
Doxazosin Mesylate18$422
NitrofurantoinNitrofurantoin Macrocrystal11$369

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$100$38,92460 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,324 urology providers in California.

Other urology in Modesto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →